Work

67P LX-101: A novel, clinical stage, payload-bearing targeted therapy directed to the insulin-like growth factor receptor (IGF-1R), demonstrates potent anti-tumor activity in Ewing sarcoma (ES) animal models and desmoplastic small round cell tumor (DSRCT)

Year: 2025

Type: article

Abstract: Multiple aggressive cancers, including ES and DSRCT, involve alterations that upregulate the IGF-1R pathway, such as gene fusions and/or high IGF-1R expression, correlating with poor outcomes. Prior IGF-1R inhibitors, mainly monoclonal antibodies and small molecules, showed some tumor responses but weren't approved potentially due to suboptimal potency and escape mechanisms via redundnat signaling. LX-101, a next-generation therapy targeting IGF-1R, couples a proprietary IGF-1 variant to a cytotoxic MTX payload.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2025.104226

Authors: M. Hoberman, D.D. Truong, R. Cardenas Zuniga, J. Ludwing

Institution: The University of Texas MD Anderson Cancer Center

Language: English

Topic: Sarcoma Diagnosis and Treatment

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,910